An electron microscopy close-up image of numerous spherical nanoparticles at high magnification, with some particles clustered together.
An electron microscopy close-up image of numerous spherical nanoparticles at high magnification, with some particles clustered together.

Redefining drug delivery.

NaDeNo’s drug delivery platform enables targeted delivery of hard-to-deliver drugs.

Our drug delivery platform enable novel and differentiated therapeutics, and we are open to partnerships and co-developments with companies in need of a versatile drug delivery technology for hard-to-deliver drugs.

Numerous applicable drug classes

Successful encapsulation of numerous drug classes across indications with high unmet need and commercial potential.

Sustainable & scalable manufacturing

NaDeNo’s nanoparticles encapsulate the drug in a patented 1-step process without any chemical modification of the drug.

Adaptive surface targeting

By functionalizing the surface, the nanoparticles can achieve various forms of chemical and/or biological targeting.

Retention and controlled release

Proven retention following various local administration routes, combined with controlled release for sustained efficacy.

Lead asset

PACAB-002 to prevent recurrence in ovarian cancer

A close-up visualization of a nanoparticle with a spherical shape, surface ligands, and encapsulated drug molecules.
A close-up visualization of a nanoparticle with a spherical shape, surface ligands, and encapsulated drug molecules.

NaDeNo’s platform-enabled lead candidate PACAB-002 will start clinical investigation in a Phase I trial beginning early 2027. PACAB-002 is intended to eradicate peritoneal micrometastases for patients with high-grade serous ovarian cancer (HGSOC), the leading cause of high recurrence and poor survival.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.